A compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof: L is O or NH; R 1 is C 1-6 alkyl, C 1-6 haloalkyl, or a 5- to 6- membered heteroaryl ring, wherein the 5- to 6-membered heteroaryl ring is substituted by 0, 1, 2, or 3 groups independently selected from fluoro, chloro, C 1-6 alkyl, and C 1-6 haloalkyl; R 2 is hydrogen or C 1-6 alkyl; R 3 is each independently selected from hydrogen, C 1-10 alkyl, arylC 0-10 alkyl, C 3-8 cycloalkylC 0-10 alkyl, -(C 1-10 alkyl)OH, C 1-10 alkoxyC 0-10 alkyl, and (C 0-10 alkyl) 1-2 aminoC 0-10 alkyl, and C 0-10 alkylcarbonylaminoC 0-10 alkyl, wherein two R 3 may join together with the carbon to which they are attached to form a 3- to 8-membered ring; R 4 is each independently selected from hydrogen and C 1-10 alkyl, wherein two R 4 may join together with the carbon to which they are attached to form a 3- to 8-membered ring; n is 0, 1, 2, 3, or 4; p is 0, 1, 2, 3, or 4; R 5 is each independently selected from hydrogen, halogen, C 1-10 alkyl, oxo, cyano, C 1-10 alkoxyC 0-10 alkyl(oxy) 0-1 , C 1-6 alkylcarbonyl, C 1-6 haloalkyl, cycloalkylC 0-10 alkyl, and -(C 1-10 alkyl)OH; wherein the group is selected from 1) C 3-12 heterocycloalkyl having at least one nitrogen, wherein the C 3-12 heterocycloalkyl is bonded to the illustrated carbonyl via a nitrogen atom; and 2) spiroheterocyclic ring having at least one nitrogen, wherein the spiroheterocyclic ring is bonded to the illustrated carbonyl via a nitrogen atom. L is O or NH; R 1 is C 1-6 alkyl, C 1-6 haloalkyl, or a 5- to 6- membered heteroaryl ring, wherein the 5- to 6-membered heteroaryl ring is substituted by 0, 1, 2, or 3 groups independently selected from fluoro, chloro, C 1-6 alkyl, and C 1-6 haloalkyl; R 2 is hydrogen or C 1-6 alkyl; R 3 is each independently selected from hydrogen, C 1-10 alkyl, arylC 0-10 alkyl, C 3-8 cycloalkylC 0-10 alkyl, -(C 1-10 alkyl)OH, C 1-10 alkoxyC 0-10 alkyl, and (C 0-10 alkyl) 1-2 aminoC 0-10 alkyl, and C 0-10 alkylcarbonylaminoC 0-10 alkyl, wherein two R 3 may join together with the carbon to which they are attached to form a 3- to 8-membered ring; R 4 is each independently selected from hydrogen and C 1-10 alkyl, wherein two R 4 may join together with the carbon to which they are attached to form a 3- to 8-membered ring; n is 0, 1, 2, 3, or 4; p is 0, 1, 2, 3, or 4; R 5 is each independently selected from hydrogen, halogen, C 1-10 alkyl, oxo, cyano, C 1-10 alkoxyC 0-10 alkyl(oxy) 0-1 , C 1-6 alkylcarbonyl, C 1-6 haloalkyl, cycloalkylC 0-10 alkyl, and -(C 1-10 alkyl)OH; wherein the group is selected from 1) C 3-12 heterocycloalkyl having at least one nitrogen, wherein the C 3-12 heterocycloalkyl is bonded to the illustrated carbonyl via a nitrogen atom; and 2) spiroheterocyclic ring having at least one nitrogen, wherein the spiroheterocyclic ring is bonded to the illustrated carbonyl via a nitrogen atom. 1) C 3-12 heterocycloalkyl having at least one nitrogen, wherein the C 3-12 heterocycloalkyl is bonded to the illustrated carbonyl via a nitrogen atom; and 2) spiroheterocyclic ring having at least one nitrogen, wherein the spiroheterocyclic ring is bonded to the illustrated carbonyl via a nitrogen atom. <EOS>